4.64 - 4.785
3.25 - 9.18
Join Discuss about NXTC with like-minded investors
Next Dividend Date
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO™ platform, NextCure studies various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.
CEO: Michael Richman
HQ: 9000 Virginia Manor Rd Ste 200 Beltsville, 20705-4214 Maryland